title: Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: C N
authors.initials: CN
authors.lastname: Sternberg
authors.forename: A
authors.initials: A
authors.lastname: Yagoda
authors.forename: H I
authors.initials: HI
authors.lastname: Scher
authors.forename: W F
authors.initials: WF
authors.lastname: Whitmore
authors.forename: H W
authors.initials: HW
authors.lastname: Herr
authors.forename: M J
authors.initials: MJ
authors.lastname: Morse
authors.forename: P C
authors.initials: PC
authors.lastname: Sogani
authors.forename: G
authors.initials: G
authors.lastname: Bosl
authors.forename: R C
authors.initials: RC
authors.lastname: Watson
authors.forename: P S
authors.initials: PS
authors.lastname: Hollander
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011300:Preoperative Care; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000628:therapy; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate